Skip to main content

PabloLapuertaMD

Internal Medicine Princeton, NJ

Chief Medical Officer, Lexicon Pharmaceuticals

Dr. Lapuerta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lapuerta's full profile

Already have an account?

Education & Training

  • Harvard Medical School
    Harvard Medical SchoolClass of 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1992 - Present
  • NJ State Medical License
    NJ State Medical License 1996 - 2025
  • NC State Medical License
    NC State Medical License 1989 - 1991

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure  
    Deepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine

Press Mentions

  • Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care
    Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes CareJune 25th, 2018
  • Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
    Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes CareJune 23rd, 2018
  • Sotagliflozin (Zynquista): A Novel SGLT Medication
    Sotagliflozin (Zynquista): A Novel SGLT MedicationJune 16th, 2018
  • Join now to see all